EP1373216B1
(fr)
*
|
2001-03-22 |
2004-12-15 |
Solvay Pharmaceuticals B.V. |
Derives de 4,5-dihydro-1h-pyrazole ayant une activite d'antagoniste de cb 1
|
US20050054730A1
(en)
*
|
2001-03-27 |
2005-03-10 |
The Regents Of The University Of California |
Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
|
TWI231757B
(en)
|
2001-09-21 |
2005-05-01 |
Solvay Pharm Bv |
1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
|
CA2442245C
(fr)
*
|
2001-09-21 |
2010-03-30 |
Solvay Pharmaceuticals B.V. |
Derives 4,5-dihydro-1h-pyrazole presentant une puissante activite antagoniste du recepteur cb1
|
DE60215960T2
(de)
|
2001-09-21 |
2007-03-01 |
Solvay Pharmaceuticals B.V. |
Neue 4,5-dihydro-1h-pyrazol-derivate mit cb1-antagonistischer wirkung
|
NZ534757A
(en)
|
2002-03-12 |
2006-07-28 |
Merck & Co Inc |
Substituted amides
|
US6825209B2
(en)
|
2002-04-15 |
2004-11-30 |
Research Triangle Institute |
Compounds having unique CB1 receptor binding selectivity and methods for their production and use
|
GB0216700D0
(en)
|
2002-07-18 |
2002-08-28 |
Astrazeneca Ab |
Process
|
WO2004013120A1
(fr)
*
|
2002-07-29 |
2004-02-12 |
F. Hoffmann-La Roche Ag |
Nouveaux benzodioxoles
|
US7765162B2
(en)
*
|
2002-10-07 |
2010-07-27 |
Mastercard International Incorporated |
Method and system for conducting off-line and on-line pre-authorized payment transactions
|
EP1556373A1
(fr)
*
|
2002-10-18 |
2005-07-27 |
Pfizer Products Inc. |
Ligands des recepteurs des cannabinoides et applications de ceux-ci
|
US7129239B2
(en)
*
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
US7247628B2
(en)
*
|
2002-12-12 |
2007-07-24 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
DE60330392D1
(de)
|
2003-01-02 |
2010-01-14 |
Hoffmann La Roche |
Cb 1 rezeptor inversagonisten
|
DE60322114D1
(de)
|
2003-01-02 |
2008-08-21 |
Hoffmann La Roche |
Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
GB0302673D0
(en)
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
US7329658B2
(en)
*
|
2003-02-06 |
2008-02-12 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
US7176210B2
(en)
*
|
2003-02-10 |
2007-02-13 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
US20040214856A1
(en)
*
|
2003-04-23 |
2004-10-28 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
US7141669B2
(en)
*
|
2003-04-23 |
2006-11-28 |
Pfizer Inc. |
Cannabiniod receptor ligands and uses thereof
|
US7268133B2
(en)
*
|
2003-04-23 |
2007-09-11 |
Pfizer, Inc. Patent Department |
Cannabinoid receptor ligands and uses thereof
|
US7145012B2
(en)
|
2003-04-23 |
2006-12-05 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
BRPI0410289A
(pt)
*
|
2003-05-07 |
2006-05-16 |
Pfizer Prod Inc |
ligantes do receptor de canabinóides e suas utilizações
|
US7232823B2
(en)
|
2003-06-09 |
2007-06-19 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
US20040259887A1
(en)
*
|
2003-06-18 |
2004-12-23 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
CA2527033A1
(fr)
*
|
2003-06-18 |
2004-12-23 |
Astrazeneca Ab |
Agents therapeutiques
|
GB0314057D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
GB0314049D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
GB0314261D0
(en)
*
|
2003-06-19 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
CN100368407C
(zh)
|
2003-06-20 |
2008-02-13 |
霍夫曼-拉罗奇有限公司 |
作为cb1受体反激动剂的2-酰氨基苯并噻唑
|
CA2537535A1
(fr)
*
|
2003-09-02 |
2005-03-10 |
Solvay Pharmaceuticals Gmbh |
Nouvelles utilisations medicales d'antagonistes selectifs du recepteur cb<sb>1</sb>
|
AR045533A1
(es)
*
|
2003-09-02 |
2005-11-02 |
Solvay Pharm Gmbh |
Uso de un compuesto antagonista de receptor de cb1, composicion farmaceutica y metodo de tratamiento y/o profilaxis de enfermedades relacionadas con dicho receptor de cb1
|
US20050239859A2
(en)
*
|
2003-09-03 |
2005-10-27 |
Solvay Pharmaceuticals Gmbh |
Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
|
TW200528102A
(en)
*
|
2003-10-24 |
2005-09-01 |
Solvay Pharm Gmbh |
Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
|
US20050124660A1
(en)
*
|
2003-10-27 |
2005-06-09 |
Jochen Antel |
Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
|
US20050143441A1
(en)
*
|
2003-10-27 |
2005-06-30 |
Jochen Antel |
Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
|
GB0327331D0
(en)
*
|
2003-11-25 |
2003-12-31 |
Astrazeneca Ab |
Therapeutic agents
|
KR100773650B1
(ko)
|
2003-12-08 |
2007-11-05 |
에프. 호프만-라 로슈 아게 |
신규한 싸이아졸 유도체
|
JP4436369B2
(ja)
|
2004-01-28 |
2010-03-24 |
エフ.ホフマン−ラ ロシュ アーゲー |
スピロ−ベンゾジオキソール類およびそれらのcb1アンタゴニストとしての使用
|
ES2311972T3
(es)
*
|
2004-01-30 |
2009-02-16 |
Solvay Pharmaceuticals B.V. |
Derivados 1,3,5-trisubstituidos de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1.
|
US7745476B2
(en)
|
2004-01-30 |
2010-06-29 |
Solvay Pharmaceuticals B.V. |
1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
|
TW200533657A
(en)
|
2004-02-17 |
2005-10-16 |
Esteve Labor Dr |
Substituted pyrazoline compounds, their preparation and use as medicaments
|
GB0403780D0
(en)
*
|
2004-02-20 |
2004-03-24 |
Astrazeneca Ab |
Therapeutic agents
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
AU2005229459B9
(en)
*
|
2004-04-03 |
2009-01-22 |
Astrazeneca Ab |
Therapeutic agents
|
ES2324720T3
(es)
|
2004-05-10 |
2009-08-13 |
F. Hoffmann-La Roche Ag |
Pirrol o imidazol amidas para tratar la obesidad.
|
ITMI20041032A1
(it)
*
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Compositi farmaceutici
|
ITMI20041033A1
(it)
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Composti farmaceutici
|
TW200602314A
(en)
|
2004-05-28 |
2006-01-16 |
Tanabe Seiyaku Co |
A novel pyrrolidine compound and a process for preparing the same
|
US20060025448A1
(en)
|
2004-07-22 |
2006-02-02 |
Cadila Healthcare Limited |
Hair growth stimulators
|
EP1807070A1
(fr)
*
|
2004-09-29 |
2007-07-18 |
Schering Corporation |
Combinaisons d'azetidinones substituees et d'antagonistes cb1
|
RU2007119315A
(ru)
|
2004-10-25 |
2008-11-27 |
Зольвай Фармасьютиклз Гмбх (De) |
Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний
|
RU2394027C2
(ru)
|
2004-10-27 |
2010-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Новые индольные или бензимидазольные производные
|
EP1812418B1
(fr)
|
2004-11-09 |
2010-10-27 |
F. Hoffmann-La Roche AG |
Derives dibenzosuberone
|
WO2006060201A2
(fr)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Derives de pyrazole utilises dans le traitement de troubles psychiatriques
|
WO2006060192A2
(fr)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Derives de pyrazole
|
WO2006060211A2
(fr)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Derives de pyrazole pour le traitement de dysfonctionnement sexuel
|
WO2006060186A2
(fr)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Derives de pyrazole pour le traitement de la demence et de troubles associes
|
ATE435207T1
(de)
|
2005-04-06 |
2009-07-15 |
Hoffmann La Roche |
Pyridin-3-carbonsäureamidderivate als cb1-inverse agonisten
|
CA2609783A1
(fr)
*
|
2005-05-27 |
2006-12-07 |
Pfizer Products Inc. |
Polytherapie pour le traitement de l'obesite ou le maintien du poids apres une perte ponderale
|
EP1902034B1
(fr)
|
2005-06-02 |
2011-03-30 |
Glenmark Pharmaceuticals S.A. |
Nouveaux ligands des recepteurs des cannabinoides, compositions pharmaceutiques contenant ces ligands, et procede servant a leur preparation
|
US7923465B2
(en)
|
2005-06-02 |
2011-04-12 |
Glenmark Pharmaceuticals S.A. |
Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
EP1743890A1
(fr)
*
|
2005-07-15 |
2007-01-17 |
Laboratorios Del Dr. Esteve, S.A. |
Dérivés 4,5-dihydro-1H-pyrazole, leur, préparation et utilisation comme médicaments.
|
WO2007009720A2
(fr)
*
|
2005-07-15 |
2007-01-25 |
Laboratorios Del Dr. Esteve S.A. |
Promedicaments de composes de pyrazoline, fabrication et utilisation comme medicaments
|
EP1749526A1
(fr)
*
|
2005-07-15 |
2007-02-07 |
Laboratorios Del Dr. Esteve, S.A. |
Utilisation des derivés de la pyrazoline pour le traitement des troubles alimentaires, comme l'obesité ou le syndrome métabolique chez les patients diabetiques
|
EP1749821A1
(fr)
*
|
2005-07-15 |
2007-02-07 |
Laboratorios Del Dr. Esteve, S.A. |
Sels de dérives pyrazoline, leur préparation et leur utilisation comme medicaments médicaments
|
ES2326460B1
(es)
*
|
2005-07-15 |
2010-04-19 |
Laboratorios Del Dr. Esteve, S.A. |
Sales de amonio cuaternario de compuestos de pirazolina sustituidos, su preparacion y uso como medicamentos.
|
EP1743892A1
(fr)
|
2005-07-15 |
2007-01-17 |
Laboratorios del Dr. Esteve S.A. |
Composés pyrazoline substitués, leur préparation et utilisation comme médicaments
|
WO2007009704A2
(fr)
*
|
2005-07-15 |
2007-01-25 |
Laboratorios Del Dr. Esteve, S.A. |
Utilisation de composes de pyrazoline substitues pour le traitement de troubles lies aux aliments, notamment l'obesite ou le syndrome metabolique chez des malades souffrant du diabete
|
EP1749820A1
(fr)
*
|
2005-07-15 |
2007-02-07 |
Laboratorios Del Dr. Esteve, S.A. |
Sels de dérives pyrazoline, leur préparation et leur utilisation comme medicaments médicaments
|
WO2007009690A1
(fr)
*
|
2005-07-15 |
2007-01-25 |
Laboratorios Del Dr. Esteve, S.A |
Composes de pyrazoline a substitution heterocyclyle, preparation et utilisation de ceux-ci comme medicaments
|
EP1928463A2
(fr)
*
|
2005-08-17 |
2008-06-11 |
Solvay Pharmaceuticals GmbH |
Methode d'utilisation de composes inhibiteurs du canal du potassium
|
JP4658134B2
(ja)
|
2005-10-04 |
2011-03-23 |
田辺三菱製薬株式会社 |
光学活性4−ヒドロキシ−1,2,3,4−テトラヒドロキノリン化合物の製法
|
AR056560A1
(es)
|
2005-10-06 |
2007-10-10 |
Astrazeneca Ab |
Pirrolopiridinonas como moduladores cb1
|
EA200870074A1
(ru)
*
|
2005-12-20 |
2008-12-30 |
Солвей Фармасьютикалс Б.В. |
Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1
|
MX2008013678A
(es)
*
|
2006-04-27 |
2008-11-04 |
Solvay Pharm Gmbh |
Compuestos farmaceuticos que comprenden moduladores de receptores de canabinoide cbx y moduladores de canal de potasio.
|
US20070254863A1
(en)
*
|
2006-04-27 |
2007-11-01 |
Jochen Antel |
Use of CBx cannabinoid receptor modulators as potassium channel modulators
|
US7763607B2
(en)
|
2006-04-27 |
2010-07-27 |
Solvay Pharmaceuticals Gmbh |
Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
|
US7482470B2
(en)
*
|
2006-05-05 |
2009-01-27 |
Jenrin Discovery, Inc. |
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
|
US7629346B2
(en)
|
2006-06-19 |
2009-12-08 |
Hoffmann-La Roche Inc. |
Pyrazinecarboxamide derivatives as CB1 antagonists
|
US7964728B2
(en)
*
|
2006-07-06 |
2011-06-21 |
Solvay Pharmaceuticals B.V. |
Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
|
RU2009108280A
(ru)
|
2006-08-08 |
2010-09-20 |
Санофи-Авентис (Fr) |
Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
|
US7781593B2
(en)
|
2006-09-14 |
2010-08-24 |
Hoffmann-La Roche Inc. |
5-phenyl-nicotinamide derivatives
|
SA07280510B1
(ar)
*
|
2006-09-22 |
2012-02-07 |
سولفاي فارماسوتيكالز بي . في |
سلفونيل بيرازول ومشتقات سلفونيل كربوكساميدين كمضادات ht6-5
|
JP5222855B2
(ja)
*
|
2006-12-18 |
2013-06-26 |
7ティーエム ファーマ エイ/エス |
Cb1受容体のモジュレーター
|
EA020466B1
(ru)
|
2007-06-04 |
2014-11-28 |
Синерджи Фармасьютикалз Инк. |
Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EP2025674A1
(fr)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
|
US7655685B2
(en)
*
|
2007-11-02 |
2010-02-02 |
Jenrin Discovery, Inc. |
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
|
TW201014822A
(en)
|
2008-07-09 |
2010-04-16 |
Sanofi Aventis |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
CA2730603C
(fr)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonistes de la guanylate cyclase utiles dans le traitement des affections gastro-intestinales, de l'inflammation gastro-intestinale, du cancer gastro-intestinal et d'autres affections
|
EP2151234A1
(fr)
*
|
2008-07-28 |
2010-02-10 |
Laboratorios Del. Dr. Esteve, S.A. |
Formulation pharmaceutique comprenant un composé récepteur CB1 dans une solution solide et/ou une dispersion solide
|
AR072539A1
(es)
*
|
2008-08-01 |
2010-09-01 |
Solvay Pharm Bv |
Sintesis de derivados de 3,4-diaril -4,5-dihidro -(1h) - pirazol -1- carboxamida
|
CN102264228A
(zh)
|
2008-10-22 |
2011-11-30 |
默沙东公司 |
用于抗糖尿病药的新的环状苯并咪唑衍生物
|
US8329914B2
(en)
|
2008-10-31 |
2012-12-11 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
WO2010068601A1
(fr)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
|
WO2010079241A1
(fr)
|
2009-01-12 |
2010-07-15 |
Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion |
Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones
|
JP2013503135A
(ja)
|
2009-08-26 |
2013-01-31 |
サノフイ |
新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
|
US8217038B2
(en)
|
2009-10-07 |
2012-07-10 |
Jenrin Discovery, Inc. |
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
|
WO2011106273A1
(fr)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques
|
EP2582709B1
(fr)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US8410107B2
(en)
|
2010-10-15 |
2013-04-02 |
Hoffmann-La Roche Inc. |
N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
|
AU2011329636B2
(en)
|
2010-11-18 |
2016-05-19 |
Jenrin Discovery |
Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
|
US8669254B2
(en)
|
2010-12-15 |
2014-03-11 |
Hoffman-La Roche Inc. |
Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
|
CA2826649C
(fr)
|
2011-02-25 |
2016-07-26 |
Merck Sharp & Dohme Corp. |
Nouveaux derives d'azabenzimidazole cyclique utiles en tant qu'agents antidiabetiques
|
WO2012120054A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
|
EP2683700B1
(fr)
|
2011-03-08 |
2015-02-18 |
Sanofi |
Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
|
WO2012120055A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
|
WO2012120051A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
US8809324B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
WO2012120053A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
|
EP2766349B1
(fr)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
|
EP2683701B1
(fr)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
|
US8680131B2
(en)
|
2012-07-25 |
2014-03-25 |
Jenrin Discovery, Inc. |
Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
|
NZ703992A
(en)
|
2012-08-01 |
2018-04-27 |
Lewis And Clark Pharmaceuticals Inc |
N-alkyl 2-(disubstituted)alkynyladenosine-5’-uronamides as a2a agonists
|
US20140045746A1
(en)
|
2012-08-02 |
2014-02-13 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US11155521B2
(en)
|
2012-11-13 |
2021-10-26 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Cannabinoid receptor mediating compounds
|
US9765031B2
(en)
|
2012-11-13 |
2017-09-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cannabinoid receptor mediating compounds
|
BR112015019836A2
(pt)
|
2013-02-22 |
2017-07-18 |
Merck Sharp & Dohme |
composto, composição farmacêutica, e, uso de um composto
|
US9650375B2
(en)
|
2013-03-14 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as anti-diabetic agents
|
CA2905435A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions utiles pour le traitement de troubles gastro-intestinaux
|
EP2970384A1
(fr)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonistes de la guanylate cyclase et leurs utilisations
|
CN113388007A
(zh)
|
2013-06-05 |
2021-09-14 |
博士医疗爱尔兰有限公司 |
鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
|
WO2015051496A1
(fr)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Composés tricycliques antidiabétiques
|
WO2015172059A1
(fr)
*
|
2014-05-09 |
2015-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Dérivés pyrazole et leur utilisation comme médiateurs des récepteurs aux cannabinoïdes
|
EP3109237A1
(fr)
|
2015-06-22 |
2016-12-28 |
AnaMar AB |
Nouveaux antagonistes de 5-ht2
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
WO2022245627A1
(fr)
|
2021-05-17 |
2022-11-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Approche facile et exempte d'odeur pour convertir des dérivés de sulfonylurée en dérivés de sulfonylurée de chalcogénure
|